Suk-Koo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suk-Koo Lee has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Choon Hyuck David Kwon
Department of Hepato-Pancreato-Biliary & Liver Transplant Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
14 shared publications - Jae-Won Joh
Department of Surgery, Samsung Medical Center, Seoul, South Korea
14 shared publications Sanghoon Lee
Department of Pediatric Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
11 shared publicationsJeong-Meen Seo
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
8 shared publicationsJong Man Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
6 shared publications- Jong Man Kim
Division of Transplantation Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (4) , 219-227
Upper thigh skeletal muscle index predicts outcomes in liver transplant recipients
Lim M, et al. Ann Surg Treat Res. 2023 Oct;105(4):219-227. https://doi.org/10.4174/astr.2023.105.4.219
- 1 January 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (4) , 219-227
Open AccessUpper thigh skeletal muscle index predicts outcomes in liver transplant recipients
Lim M, et al. Ann Surg Treat Res. 2023 Oct;105(4):219-227. https://doi.org/10.4174/astr.2023.105.4.219
- Open Access
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (3) , 181-188
Severe Anemia Caused by Parvovirus B19 Infection in Two Pediatric Kidney Transplantation Recipients
김경란, et al. Pediatr Infect Vaccine. 2021 Dec;28(3):181-188. https://doi.org/10.14776/piv.2021.28.e19
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (3) , 181-188
Open AccessSevere Anemia Caused by Parvovirus B19 Infection in Two Pediatric Kidney Transplantation Recipients
김경란, et al. Pediatr Infect Vaccine. 2021 Dec;28(3):181-188. https://doi.org/10.14776/piv.2021.28.e19
- Open Access
- 4 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1833
Risk factors of silent allograft fibrosis 10 years post-pediatric liver transplantation
This study analyzed factors related to allograft fibrosis in clinically stable pediatric liver transplantation patients. Pediatric patients who underwent liver transplantation from January 1997 to January 2008 and further underwent 10-year protocol biopsies were examined. Grades of inflammation and fibrosis were classified based on Banff criteria and the Liver Allograft Scoring (LAF) system, respectively. Risk factors for fibrosis were analyzed using logistic regression. Sixty-six patients with no clinical signs of chronic liver disease were included. Forty-one patients out of 66 (62.1%) had certain stage of allograft fibrosis. More than five events with aminotransferase >50 U/L was a risk factor for a LAF score 1–2 portal fibrosis (OR = 3.156, CI 1.059–9.410, P = 0.039). More than five events with aminotransferase >100 U/L was a risk factor for LAF score 2 portal fibrosis (OR = 13.978, CI 2.025–97.460, P = 0.007) and LAF score 1–2 sinusoidal fibrosis (OR = 4.897, CI 1.167–20.548, P = 0.030). Positive autoantibody (OR = 3.298, CI 1.039–10.473, P = 0.043) and gamma-glutamyl transferase 60 U/L (OR = 6.201, CI 1.096–35.097, P = 0.039) were related to sinusoidal fibrosis with LAF score of 1–2 and 2, respectively. Experience of post-transplantation lymphoproliferative disease was related to LAF score 1–2 portal fibrosis (OR = 7.371, CI 1.320–41,170, P = 0.023) and LAF score 1–2 centrolobular fibrosis (OR = 8.822, CI = 1.378–56.455, P = 0.022). Our results indicate that liver fibrosis is common in patients with no clinical signs of graft deterioration and repeated elevation of aminotransferases, positive autoantibodies, elevated gamma-glutamyl transferase and experience of post-transplantation lymphoproliferative disease are suspicious signs for fibrosis.
- 4 February 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1833
Open AccessRisk factors of silent allograft fibrosis 10 years post-pediatric liver transplantation
This study analyzed factors related to allograft fibrosis in clinically stable pediatric liver transplantation patients. Pediatric patients who underwent liver transplantation from January 1997 to January 2008 and further underwent 10-year protocol biopsies were examined. Grades of inflammation and fibrosis were classified based on Banff criteria and the Liver Allograft Scoring (LAF) system, respectively. Risk factors for fibrosis were analyzed using logistic regression. Sixty-six patients with no clinical signs of chronic liver disease were included. Forty-one patients out of 66 (62.1%) had certain stage of allograft fibrosis. More than five events with aminotransferase >50 U/L was a risk factor for a LAF score 1–2 portal fibrosis (OR = 3.156, CI 1.059–9.410, P = 0.039). More than five events with aminotransferase >100 U/L was a risk factor for LAF score 2 portal fibrosis (OR = 13.978, CI 2.025–97.460, P = 0.007) and LAF score 1–2 sinusoidal fibrosis (OR = 4.897, CI 1.167–20.548, P = 0.030). Positive autoantibody (OR = 3.298, CI 1.039–10.473, P = 0.043) and gamma-glutamyl transferase 60 U/L (OR = 6.201, CI 1.096–35.097, P = 0.039) were related to sinusoidal fibrosis with LAF score of 1–2 and 2, respectively. Experience of post-transplantation lymphoproliferative disease was related to LAF score 1–2 portal fibrosis (OR = 7.371, CI 1.320–41,170, P = 0.023) and LAF score 1–2 centrolobular fibrosis (OR = 8.822, CI = 1.378–56.455, P = 0.022). Our results indicate that liver fibrosis is common in patients with no clinical signs of graft deterioration and repeated elevation of aminotransferases, positive autoantibodies, elevated gamma-glutamyl transferase and experience of post-transplantation lymphoproliferative disease are suspicious signs for fibrosis.
- Open Access
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 99 (1) , 52-62
Perioperative risk factors of progressive chronic kidney disease following liver transplantation: analyses of a 10-year follow-up single-center cohort
Lee K, et al. Ann Surg Treat Res. 2020 Jul;99(1):52-62. https://doi.org/10.4174/astr.2020.99.1.52
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 99 (1) , 52-62
Open AccessPerioperative risk factors of progressive chronic kidney disease following liver transplantation: analyses of a 10-year follow-up single-center cohort
Lee K, et al. Ann Surg Treat Res. 2020 Jul;99(1):52-62. https://doi.org/10.4174/astr.2020.99.1.52
- 16 May 2019
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 25 (3) , 231-237
Stent insertion and balloon angioplasty for portal vein stenosis after liver transplantation: long-term follow-up results
Diagnostic and Interventional Radiology
- 16 May 2019
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 25 (3) , 231-237
Stent insertion and balloon angioplasty for portal vein stenosis after liver transplantation: long-term follow-up results
Diagnostic and Interventional Radiology
- Open Access
- 31 March 2019
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 33 (1) , 1-5
Pediatric liver transplantation in Korea: long-term outcomes and allocations
Lee S, et al. J Korean Soc Transplant. 2019 Mar;33(1):1-5. https://doi.org/10.4285/jkstn.2019.33.1.1
- 31 March 2019
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 33 (1) , 1-5
Open AccessPediatric liver transplantation in Korea: long-term outcomes and allocations
Lee S, et al. J Korean Soc Transplant. 2019 Mar;33(1):1-5. https://doi.org/10.4285/jkstn.2019.33.1.1
- 1 November 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (9) , 2668-2674
Early Vs Late Liver Retransplantation: Different Characteristics and Prognostic Factors
- 1 November 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (9) , 2668-2674
Early Vs Late Liver Retransplantation: Different Characteristics and Prognostic Factors
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S108
Phase 1/2a trial of a bioartificial liver support system for acute liver failure patients
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S108
Phase 1/2a trial of a bioartificial liver support system for acute liver failure patients
- Open Access
- 16 May 2017
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-11
Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT), the survival rate was encouraging; however, short- and long-term toxicities were significant. In the present SMC NB-2009 study, only TBI was replaced with 131I-meta-iodobenzylguanidine (MIBG) treatment in order to reduce toxicities. From January 2009 to December 2013, 54 consecutive patients were assigned to receive tandem HDCT/auto-SCT after nine cycles of induction chemotherapy. The CEC (carboplatin + etoposide + cyclophosphamide) regimen and the TM (thiotepa + melphalan) regimen with (for metastatic MIBG avid tumors) or without (for localized or MIBG non-avid tumors) 131I-MIBG treatment (18 or 12 mCi/kg) were used for tandem HDCT/auto-SCT. Local radiotherapy, differentiation therapy with 13-cis-retinoic acid, and immunotherapy with interleukin-2 were administered after tandem HDCT/auto-SCT. Fifty-two patients underwent the first HDCT/auto-SCT and 47 patients completed tandem HDCT/auto-SCT. There was no significant immediate toxicity during the 131I-MIBG infusion. Acute toxicities during the tandem HDCT/auto-SCT were less severe in the NB-2009 study than in the NB-2004 study. Late effects such as growth hormone deficiency, cataracts, and glomerulopathy evaluated at 3 years after the second HDCT/auto-SCT were also less significant in the NB-2009 study than in NB-2004 study. There was no difference in the 5-year event-free survival (EFS) between the two studies (67.5 ± 6.7% versus 58.3 ± 6.9%, P = 0.340). Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate. ClinicalTrials.gov NCT03061656
- 16 May 2017
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-11
Open AccessIncorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT), the survival rate was encouraging; however, short- and long-term toxicities were significant. In the present SMC NB-2009 study, only TBI was replaced with 131I-meta-iodobenzylguanidine (MIBG) treatment in order to reduce toxicities. From January 2009 to December 2013, 54 consecutive patients were assigned to receive tandem HDCT/auto-SCT after nine cycles of induction chemotherapy. The CEC (carboplatin + etoposide + cyclophosphamide) regimen and the TM (thiotepa + melphalan) regimen with (for metastatic MIBG avid tumors) or without (for localized or MIBG non-avid tumors) 131I-MIBG treatment (18 or 12 mCi/kg) were used for tandem HDCT/auto-SCT. Local radiotherapy, differentiation therapy with 13-cis-retinoic acid, and immunotherapy with interleukin-2 were administered after tandem HDCT/auto-SCT. Fifty-two patients underwent the first HDCT/auto-SCT and 47 patients completed tandem HDCT/auto-SCT. There was no significant immediate toxicity during the 131I-MIBG infusion. Acute toxicities during the tandem HDCT/auto-SCT were less severe in the NB-2009 study than in the NB-2004 study. Late effects such as growth hormone deficiency, cataracts, and glomerulopathy evaluated at 3 years after the second HDCT/auto-SCT were also less significant in the NB-2009 study than in NB-2004 study. There was no difference in the 5-year event-free survival (EFS) between the two studies (67.5 ± 6.7% versus 58.3 ± 6.9%, P = 0.340). Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate. ClinicalTrials.gov NCT03061656